AstraZeneca has agreed to buy Bristol-Myers Squibb’s stake in the companies’ diabetes joint venture for up to $4.1 billion in a deal that will help return the group to growth, sending its shares to a new high. AstraZeneca said on Thursday that it would pay Bristol an initial $2.7 billion plus up to $1.4 billion in additional regulatory and sales-related payments. The move will bulk up AstraZeneca’s thin drug portfolio and give Bristol more funds to invest in other areas, such as cancer, where it is developing promising therapies tapping into the immune system.
Help employers find you! Check out all the jobs and post your resume.
